

## Investor Statement Access to Medicine Index

The goal of investors is to create long-term shareholder value in the companies in which they invest. This potential is maximized by investing in well-managed, high quality companies, where the management team have considered fully the range of business risks and opportunities facing their companies, and taken appropriate action to manage these. Alongside assessment of traditional financial risks and opportunities, there is growing recognition among the investment community of the potential for environmental, social and governance (ESG) factors to impact the financial performance of companies. As such, investors are also seeking for companies to demonstrate effective management of ESG factors.

We believe the issue of access to medicine in developing countries can present potentially significant business impacts for global companies in the pharmaceutical sector. As greater emphasis is placed on accessing new markets as a source for future industry growth, pharmaceutical companies are brought into ever closer contact with access to medicine issues in developing countries. Mismanagement of these issues can impact negatively on political relationships and corporate brands and encumber market access. On the other hand, if pharmaceutical companies act responsibly and with foresight, commercial potential can be unlocked.

As investors, we seek assurances that the management of the companies in which we invest have fully considered the risks and opportunities of this issue, and have effective policies and processes for dealing with the challenges. By taking management of this issue into account, alongside other key ESG and financial issues, the investment community can better assess the long-term investment value of such companies. We are increasingly reviewing corporate approaches to access to medicine and associated aspects of intellectual property as a key strategic consideration in our analysis of the sector, where this is appropriate to do so.

It is in this context that the investors listed below welcome the development of analytical tools such as the Access to Medicine Index, which may be used by investors to assess companies' management of the issue, based on information obtained from their reporting activities.

By our explicit inclusion in this statement, we are agreed on the following:

- We believe the issue of access to medicine is potentially material to long-term shareholder value creation, and is a potentially relevant consideration when forming views on the strategic positioning of companies in the pharmaceutical sector. We welcome the Access to Medicine Foundation's efforts to develop a credible, transparent and independent tool, which could be useful with regards to specific issue.
- We consider that pharmaceutical companies have an important role to play in addressing the access to medicine issue;
- We will review and take into account the analysis generated from the Index as appropriate in the ESG analysis we conduct on the companies we invest in;
- We hope that the Index will contribute towards creating greater awareness within the industry of this important issue, and act as a tool for highlighting leadership and good practice, as well as gaps and challenges;
- We will provide investor input into the evolution of the Index to ensure it considers the investment perspective as appropriate and remains dynamic and relevant to the debate.

We would encourage other investors to join us in this statement.

## SIGNATORY INVESTORS





## TOTAL ASSETS UNDER MANAGEMENT IN EXCESS OF USD 21 TRILLION

For more information please contact Mara Lilley mlilley@accesstomedicinefoundation.org





Aberdeen Standard Investments Achmea Adrian Dominican Sisters Aegon Nederland N.V. Aequo and Hexavest Aikya Investment Management	Andrew Mason Jeroen Wiercx Donna Meyer	JLens Investment Network Joh. Berenberg, Gossler & Co. KG (Berenberg)	Rabbi Joshua Ratner Dr. Rupini Rajagopalan
Adrian Dominican Sisters Aegon Nederland N.V. Aequo and Hexavest Aikya Investment Management		Joh. Berenberg, Gossler & Co. KG (Berenberg)	Dr. Rupini Rajagopalan
Aegon Nederland N.V. Aequo and Hexavest Aikya Investment Management	Donna Meyer		
Aequo and Hexavest Aikya Investment Management		Kempen Capital Management	Eszter Vitorino
Aikya Investment Management	Willem Horstmann	Kieger AG	Panagiota Balfousia
	Arnaud Celka	La Banque Postale Asset Management	Luisa Florez
and the second s	Tom Allen	La Financiere de l'Echiquier	Coline Pavot
Alecta	Peter Loow	Länsförsäkringar AB	Kristofer Dreiman
AllianceBernstein	Saskia Kort-Chick	Legal & General Investment Management	Maria Larsson Ortino
American Century Investments	Guillaume Mascotto	Local Government Super	Moya Yip
Amundi Asset Management	Caroline Le Meaux	M&G Investments	Ben Constable Maxwell
APG Asset Management	Els Knoope	Mercy Investment Services	Donna Meyer
Apostle Funds Management	Fiona Manning	Miller/Howard Investments	Luan Steinhilber
ASN Beleggingsfondsen	Piet Sprengers	Mirova	Manon Salomez
ASR Nederland NV	Jack Julicher	Mitsubishi UFJ Trust and Banking Corporation	Masahiro Kato
Asset Management One	Toru Terasawa	MN	Louis Kranenburg
Auriga Partners	Jacques Chatain	Natixis	Marina Iodice
Australian Ethical Investment	Stuart Palmer	NEIInvestments	Jamie Bonham
Aviva Investors	Steve Waygood	NN Investment Partners	Adrie Heinsbroek
AXA Investment Managers	Gilles Moec	Nomura Asset Management	Toshiyuki Imamura
BancoPosta Fondi S.p.A. SGR	Stefano Giuliani	Nordea Asset Management	Magdalena Kettis
BNP Paribas Investment Partners	Helena Vines Fiestas	Northwest Coalition for Responsible	Judy Byron
Bon Secours Mercy Health	Donna Meyer	Investment	
Boston Common Asset Management	Lauren Compere	OFI Asset Management	Eric Van La Beck
Boston Trust Walden Company	Heidi Soumerai	Öhman	Fredric Nystrom
Calvert Research and Management	Stuart Dalheim	Parnassus Investments	Benjamin Allen
Candriam Investors Group	Sophie Deleuze	Pax World Funds	Joe Keefe
Cardano	Colette Grosscurt	Pensioenfonds Medewerkers Apotheken (PMA)	Remco Velasquez
Castlefield Investment Partners	Mark Elliot	PGGM	Rogier Snijdewind
CCLA Investment Management	Amy Browne	Poste Vita S.p.A.	Antonio Colombi
Central Finance Board of the Methodist Churc	h Christophe Borysiewicz	Quaestio Capital SGR Spa	Mario Baronci
Church of Sweden	Sara Nordbrand	Radicant Bank AG	Eve Morelli
ClearBridge Investments	Marshall Gordon	RAM Active Investments SA	Cyrille Joye
Coho Partners	Nimrit Kang	Rathbone Greenbank Investments	Matt Crossman
Columbia Threadneedle Investments	Catherine McCabe	Reynders, McVeigh Capital Management, LLC	Maria Egan
Cometa Pension Fund	Maurizio Agazzi	Robeco	Peter van der Werf
Comgest	Sebastien Thevoux-Chabuel	Royal London Asset Management	Ashley Claxton
Coöperatie VGZ UA	Erik Jan van Bergen	Schroders	Seema Suchak
C-QUADRAT Asset Management GmbH	Günther Kastner	SEB Investment Management AB	Anette Andersson
Crédit Mutuel Asset Management	Isabelle Delattre	SPH	Bram Stageman
CZ Fund Management BV	Yvo Boon	SPMS	Marcel Roberts
Dana Investment Advisors	Ann Roberts	Stewart Investors	Jennifer Stephen
Daughters of Charity, Province of St. Louise	Donna Meyer	Stichting Algemeen Pensioenfonds Unilever	Willy Westerborg
Decatur Capital Management, Inc.	Rosanne Lissow	Nederland	
Dignity Health	Donna Meyer	Storebrand Asset Management	Matthew Smith
DNB Asset Management	Lise Børresen	Sumitomo Mitsui Trust Asset Management	Seiji Kawazoe
Domini Impact Investments LLC	Carole Laible	Swedbank Robur Fonder AB	Pia Gisgård
ECO Advisors	Roz Yazdan	Sycomore Asset Management	Bertille Knuckey
Ecofi Investissements	Francois Lett	T. Rowe Price	Maria Elena Drew
EdenTree Investment Management	Ketan Patel	The Congregation of St. Joseph	Donna Meyer
Edmond de Rothschild Asset Management	Adeline Salat-Baroux	The Dai-ichi Life Insurance Company, Limited	
(France)		The Sisters of St. Francis of Philadelphia	Nora Nash
EFG Asset Management	Stefano Montobbio	The Socially Responsible Investing Group of	Alison Bevilacqua
EGAMO	Jérôme Tendeau	1919 Investment Counsel The Sustainability Croup of Loring, Welcott	Larica Duoff
EOS at Federated Hermes	Kimberley Lewis	The Sustainability Group of Loring, Wolcott & Coolidge	Larisa Ruoff
Epworth Investment Management	Christophe Borysiewicz	Tokio Marine Asset Management Co., Ltd.	Yo Mizuno
Ethical Partners Funds Management	Robyn Parkin	Trillium Asset Management	Jonas Kron
Ethos	Vincent Kaufmann	Trinity Health	Cathy Rowan
Etica Sgr - Responsible Investments	Luca Mattiazzi	Triodos Investment Management	Erik Breen
Fondita Fund Management Company	Janna Haahtela	Trusteam Finance	Claire Berthier
Forma Futura AG	Doris Hauser	Unigestion	Eric Cockshutt
GAM Investments	Mark Harland	Union Investment	Dr. Henrik Pontzen
Groupama AM	Jana Celeste	United Church Funds	Charles Buck
Groupe MACSF	Luc Deschamps	USS	Daniel Summerfield
Harmonie Mutuelle	Aurelien Bon	Valori Asset Management	Giancarlo Fragomeno
Hexavest	Jo-Annie Pinto		-
HSBC Asset Management	Christine Chow,	Vancity Investment Management Varma Mutual Pension Insurance Company	Kelly Hirsch Kaisa Ojainmaa
Ibercaja Gestión	Miriam Fernández Jiménez	Vontobel	Natalia Ernst
ICCR	Meg Jones-Monteiro		
Impax Asset Management and Pax World Fund		Wesleyan Group	Milly Mcloughlin
Indecap	Mats Lagerqvist	WHEB Asset Management	Seb Beloe
J. Safra Sarasin	Jullia Wittenberg	Zevin Asset Management	Pat Miguel Tomaino
Janus Henderson	Antony Marsden	Zürcher Kantonalbank	Dr. Jürgen Siemer
Jennison Associates LLC	Linda Galsim		